---
title: "RPG Life Sciences Ltd (RPGLIFE) — Share Price, Financials & Analysis"
symbol: "RPGLIFE"
company: "RPG Life Sciences Ltd"
canonical: "https://tapetide.com/stocks/RPGLIFE"
isin: "INE105J01010"
nse_symbol: "RPGLIFE"
bse_code: "532983"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 4498.78
generated_at: "2026-09-13T19:37:18.694Z"
---

# RPG Life Sciences Ltd (RPGLIFE)

Canonical page: https://tapetide.com/stocks/RPGLIFE

## Company

- **NSE Symbol:** RPGLIFE
- **BSE Code:** 532983
- **ISIN:** INE105J01010
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2008-06-10
- **CEO:** Mr. Ashok Nair
- **Employees:** 1331
- **Face Value:** ₹8
- **F&O Eligible:** No
- **Website:** rpglifesciences.com

## About

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]

## Latest Price

- **Price:** ₹2698.6
- **Change:** -84.1 (-3.02%)
- **Open:** ₹2794.3
- **Day High:** ₹2794.3
- **Day Low:** ₹2680
- **Previous Close:** ₹2782.7
- **Volume:** 17821
- **As Of:** 2026-09-11T10:23:27+00:00

## Key Fundamentals

Observed at 2026-09-11T04:52:18.598640Z.

- **Market Cap:** ₹4498.78 Cr
- **Classification:** Microcap
- **P/E (reported):** 38.4
- **P/E (TTM):** 37.37
- **EPS (TTM):** ₹72.22
- **EPS (reported):** ₹55.82
- **Book Value:** ₹366.01
- **Price to Book:** 7.59
- **Dividend Yield:** 0.86%
- **ROE:** 19.03%
- **ROCE:** 24.52%
- **Debt to Equity:** 0.03
- **Revenue (yearly):** ₹733.1 Cr
- **Net Income:** ₹115.2 Cr
- **EBITDA:** ₹172.7 Cr
- **52-Week High:** ₹3082
- **52-Week Low:** ₹1733
- **RSI (14):** 58.03

## Tapetide Score

- **Score:** 60 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 87.9 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 90.04 | 9% |
| growth | 42.82 | 9% |
| momentum | 70.35 | 12% |
| ownership | 70.43 | 24% |
| quality | 57.15 | 22% |
| valuation | 43.07 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 28.8%

### Weaknesses

- Stock is trading at 7.37 times its book value
- Debtor days have increased from 46.5 to 60.2 days.
- Working capital days have increased from 44.6 days to 63.7 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -27.43% | 823.2% | 617.01% |
| ebitda margin growth | 3.67% | -8.97% | — | — |
| net income growth | 3.01% | -37.12% | 17% | 22% |
| revenue growth | 5.25% | 10.06% | 11% | 13% |
| roce | 3.7% | -43.5% | — | — |
| roe | 2.88% | -44.9% | — | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| Expenses | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 | 152 |
| Operating Profit | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 | 39 | 40 | 33 | 44 |
| OPM % | 24 | 25 | 16 | 24 | 27 | 28 | 18 | 21 | 21 | 22 | 19 | 22 |
| Other Income | 2 | 2 | 2 | 2 | -25 | 3 | 115 | 5 | 16 | -5 | 13 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 | 49 | 29 | 40 | 41 |
| Tax % | 26 | 26 | 25 | 26 | 72 | 26 | 13 | 26 | 25 | 24 | 26 | 26 |
| Net Profit | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS in Rs | 15.64 | 16 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.9 | 22.28 | 13.38 | 18.08 | 18.48 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 708 | 734 |
| Expenses | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | 560 | 579 |
| Operating Profit | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 | 148 | 155 |
| OPM % | 11 | 10 | 16 | 18 | 20 | 20 | 22 | 25 | 21 | 21 |
| Other Income | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | 29 | 28 |
| Interest | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 | 21 | 22 |
| Profit before tax | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 | 154 | 160 |
| Tax % | 34 | 28 | 20 | 25 | 30 | 26 | 26 | 21 | 25 | — |
| Net Profit | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | 115 | 119 |
| EPS in Rs | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.9 | 53 | 110.79 | 69.64 | 72.22 |
| Dividend Payout % | 30 | 37 | 23 | 30 | 31 | 29 | 30 | 22 | 34 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 | 592 |
| Borrowings | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 | 20 |
| Other Liabilities | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | 168 |
| Total Liabilities | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 793 |
| Fixed Assets | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 | 197 |
| CWIP | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 | 120 |
| Other Assets | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | 454 |
| Total Assets | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 793 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 7 | 15 | 46 | 50 | 58 | 65 | 91 | 94 | 78 | 56 |
| Cash from Investing Activity | -30 | -16 | -19 | -11 | -8 | -35 | -106 | -79 | -42 | 51 |
| Cash from Financing Activity | 23 | 0 | -26 | -39 | -10 | -14 | -17 | -20 | -27 | -21 |
| Net Cash Flow | 1 | -1 | 0 | 0 | 40 | 17 | -32 | -5 | 9 | 87 |
| Free Cash Flow | -48 | -1 | 26 | 39 | 50 | 41 | 58 | 25 | 151 | -9 |
| CFO/OP | 58 | 48 | 144 | 94 | 94 | 96 | 111 | 96 | 81 | 63 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 | 60 |
| Inventory Days | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 | 179 |
| Days Payable | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 | 141 |
| Cash Conversion Cycle | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 | 99 |
| Working Capital Days | 20 | 22 | 20 | 41 | 52 | 47 | 33 | 25 | 45 | 64 |
| ROCE % | 10 | 13 | 10 | 23 | 27 | 31 | 33 | 35 | 33 | 26 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 72.81% | 72.81% | 72.81% | 72.81% | 72.81% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| FIIs | 0.46% | 0.56% | 0.89% | 1.14% | 1.35% | 1.3% | 1.45% | 1.35% | 1.11% | 1% | 0.87% | 0.95% |
| DIIs | 3.59% | 3.79% | 4.19% | 4.63% | 5.45% | 6.06% | 6.14% | 6.48% | 6.7% | 7.04% | 7.45% | 8.67% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 18.41% | 18.16% | 17.41% | 16.79% | 15.92% | 15.58% | 15.33% | 15.46% | 15.37% | 15.17% | 14.98% | 13.88% |
| Others | 4.73% | 4.67% | 4.7% | 4.62% | 4.47% | 4.11% | 4.12% | 3.76% | 3.88% | 3.83% | 3.74% | 3.54% |
| No. of Shareholders | 21088 | 21866 | 22137 | 22232 | 23481 | 24891 | 24867 | 25832 | 26657 | 25905 | 25282 | 23886 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 10 / 7 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2692.77 | Buy |
| EMA (10) | 2709.33 | Sell |
| SMA (20) | 2661.83 | Buy |
| EMA (20) | 2690.82 | Buy |
| SMA (50) | 2730.25 | Sell |
| EMA (50) | 2641.95 | Buy |
| SMA (100) | 2490.52 | Buy |
| EMA (100) | 2520.04 | Buy |
| SMA (200) | 2285.72 | Buy |
| EMA (200) | 2395 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 51.03 | Neutral |
| MACD (12,26,9) | 16.28 | Buy |
| Stochastic (14,3,3) | 58.15 | Neutral |
| ADX (14) | 21.02 | Neutral |
| Williams %R (14) | -55.81 | Neutral |
| ATR (14) | 112.16 | High Volatility |
| ROC (12) | 4.08 | Buy |
| Stoch RSI (14) | 58.73 | Neutral |
| UO (7,14,28) | 43.31 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 1 analyst ratings, observed at 2026-09-11T04:52:18.712423+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Update On Investment And Shareholder Agreement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd3c964e-0e91-4c92-8c62-3c681883e575.pdf) |
| 2026-09-04 | [Outcome Of Investors Meet](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b580fe84-db1b-4b55-9d66-189e3beb9700.pdf) |
| 2026-09-03 | [Investors Meet](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c0e9eed-ce2b-45c3-bb0c-7a99e985a872.pdf) |
| 2026-09-02 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d5cb0ab7-56d8-41d7-8a2f-59bb56d82651.pdf) |
| 2026-09-02 | [Intimation Of Execution Of BTA By RPG Active Pharma Limited (WOS) With Raghava Life Sciences Private Limited](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9911a4c-4cc8-47a8-9616-9d4057754cff.pdf) |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1afa8370-b91e-4bda-80e3-0ffdaf4d0c90.pdf) |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8ce2349-cfcb-4183-925d-d28dff6eac9b.pdf) |
| 2026-09-01 | [Cancellation Of Investor Meet](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0631655-b088-4e25-ae6d-7813d1fafc77.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=13d8c146-b5f5-44db-9f33-bab083cbed67.pdf) |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f746f845-6050-4081-a5ad-36c4338e866e.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b513ed76-ec95-46b0-b8a5-2a89256a8cb3.pdf) |
| 2026-07-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10b95483-f36f-4a9e-960b-724aaec608dd.pdf) |
| 2026-05-25 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41c35e63-27af-4d5d-bbf5-e7daa8201480.pdf) |
| 2026-04-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=669ab338-95d2-4ac7-91c9-9a8053a64eee.pdf) |
| 2026-01-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ba8526fd-67e9-4a90-b801-0efbe3504f4f.pdf) |
| 2026-01-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3249c429-2e6c-4f5d-af4c-2501f62a0704.pdf) |
| 2025-10-17 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71ac5e3d-7c6e-41ce-98ae-80cf42a5113a.pdf) |
| 2025-07-25 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe61fba0-e96e-409d-a10b-8198353f80e5.pdf) |
| 2025-06-02 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=57c2d7fe-cf03-4f5c-b358-cb15d0d163ba.pdf) |
| 2025-04-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21a0ec4a-d895-44a4-b20c-108859d5a5d4.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-28 | [Unaudited Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c873e3fe-35b4-4f9c-96f7-321d20e3ad1d.pdf) |
| 2026-04-29 | [Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d68cd4ef-5ed0-41d1-86dd-eafb1a59efe4.pdf) |
| 2026-01-27 | [Financial Result Quarter Ended On December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cfd8c930-cd44-45ff-a474-e14a05631c0c.pdf) |
| 2025-10-17 | [RPG Life Sciences Limited Has Submitted To The Exchange The Financial Results For The Quarter And Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e2d37dd0-303b-461b-8ac0-1ddb3fbc0dde.pdf) |
| 2025-07-25 | [Unaudited Financial Result For The Quarter Ended On June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d653033-6ed1-40a4-957f-7e772121ce8a.pdf) |
| 2025-04-28 | [Financial Result For Quarter And Year Ended On March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d53aeab0-10c4-4eea-8227-e73b9b7732b2.pdf) |
| 2025-01-24 | [Unaudited Financial Results For The Period Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ed23fab-b982-4b54-8c51-c8368059941c.pdf) |
| 2024-11-07 | [Results For Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eaad3172-b069-4059-8ef7-8467de0489da.pdf) |
| 2024-07-19 | [Unaudited Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b031e64-3770-4194-b167-7f2de631ab29.pdf) |
| 2024-04-30 | [Outcome Of Board Meeting Of The Company Held On April 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d68a234-5f2c-4cf1-980e-7f85ba067a2a.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Compliance certificate under Regulation 74(5) for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr - Compliance certificate under Regulation 74(5) for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d7b622d5-f095-4e0a-a39f-5ccfc42d323d.pdf) |
| 8h - Board meets April 29, 2026 to approve FY26 audited results and consider dividend. | [Board Meeting Intimation for The Company Has Informed BSE That The Meeting Of The Board Of The Company Is Scheduled On 29Th April, 2026 8h - Board meets April 29, 2026 to approve FY26 audited results and consider dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/fefa0b5d-934d-4f28-a6d7-93a370cbd2d3.pdf) |
| 8 May - Company informed about Transcript of Earnings Call. | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 8 May - Company informed about Transcript of Earnings Call.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/550aabb6-479b-4658-8c0f-81c2c961c6e0.pdf) |
| 7 Apr - Newspaper Advertisement in respect to Special Window opened for lodgment of transfer and dematerialization request(s). | [Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Apr - Newspaper Advertisement in respect to Special Window opened for lodgment of transfer and dematerialization request(s).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9c811710-5aee-4737-8409-bf05c20eb8c4.pdf) |
| 6h - RPG Life Sciences reported FY26 revenue growth and recommended Rs 24 dividend per share. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6h - RPG Life Sciences reported FY26 revenue growth and recommended Rs 24 dividend per share.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/6060a9bf-0675-4f3b-ad89-874ad9f05290.pdf) |
| 6h - Board approved FY26 audited results, recommended Rs24 dividend, appointed Dr. Pratit Samdani as independent director. | [Announcement under Regulation 30 (LODR)-Change in Management 6h - Board approved FY26 audited results, recommended Rs24 dividend, appointed Dr. Pratit Samdani as independent director.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/df081234-7807-40d1-a9ba-d108bdf13870.pdf) |
| 6 Apr - RPG Life Sciences relays IEPFA’s 100 Days Campaign for unclaimed dividends and KYC updates. | [Intimation To Exchange About "Second -100 Days Campaign - Saksham Niveshak" 6 Apr - RPG Life Sciences relays IEPFA’s 100 Days Campaign for unclaimed dividends and KYC updates.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bdecdb6d-250e-4cd2-9d1b-62e8275348ad.pdf) |
| 30 Jan - Agreement with First Energy for wind-solar captive power; up to Rs1.50 crore equity subscription for Ankleshwar plant. | [General Updates 30 Jan - Agreement with First Energy for wind-solar captive power; up to Rs1.50 crore equity subscription for Ankleshwar plant.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8d1c654a-abd4-4d02-ab6c-6a966f1ba7e5.pdf) |
| 30 Apr - Audio recording of Q4 FY26 results earnings call available on website on April 30, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Apr - Audio recording of Q4 FY26 results earnings call available on website on April 30, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d30a6519-e97a-44a6-98ca-dc3811780153.pdf) |
| 30 Apr - Audio recording of Q4 FY26 results earnings call available on website on April 30, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Apr - Audio recording of Q4 FY26 results earnings call available on website on April 30, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d30a6519-e97a-44a6-98ca-dc3811780153.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-05-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=550aabb6-479b-4658-8c0f-81c2c961c6e0.pdf) |
| 2025-10-24 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=01fb77ab-399e-4201-8f6d-115fe7c69397.pdf) |
| 2025-05-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a291a883-83d5-4759-b606-f11e746410f0.pdf) |
| 2024-11-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f61bc910-efbc-43a9-bdd4-a5e46fdb263b.pdf) |
| 2024-05-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4840999-1371-49db-a133-3c69378135a9.pdf) |
| 2023-10-25 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ef73901-38ca-4a78-9917-f893d2ae51d1.pdf) |
| 2023-05-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbd82909-206a-4d47-bf7c-fb5ba3608703.pdf) |
| 2022-10-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9bd87bd6-1ad6-47af-be06-0264f6e4b1ee.pdf) |
| 2022-05-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e41bf79c-a756-4806-9108-5954290ee72a.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2022 | [Concall - Sep 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1258daac-eba7-49b9-ac8b-fae5f124b9a2.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a2e112c0-3803-4f32-90f5-0bbd490631a1.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/41c35e63-27af-4d5d-bbf5-e7daa8201480.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/41c35e63-27af-4d5d-bbf5-e7daa8201480.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/57c2d7fe-cf03-4f5c-b358-cb15d0d163ba.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9351c4d6-b785-4f3c-9595-5236dd084131.pdf) |
| Jun 2023 | [Concall - Jun 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6894217-755e-4d69-a517-627d00f86ae3.pdf) |
| Jun 2023 | [Concall - Jun 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f6894217-755e-4d69-a517-627d00f86ae3.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fe61fba0-e96e-409d-a10b-8198353f80e5.pdf) |
| Jul 2024 | [Concall - Jul 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b871eab2-5f0d-49e7-8bd6-38d315753222.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/81a70887-aa9c-4fe7-9158-e91513151a6d.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/34464791-ac66-4d0e-8a8f-60419591c335.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9aca35a6-5036-4d8d-a69f-99c280ac2060.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/28ae81d6-9775-4434-8c07-936084193a40.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2025-04-29 | [Earning Call Audio Recording Link For Q$ Ended On March 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cd4bb53-b211-4c19-9212-803160783b9b.pdf) |
| 2024-11-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df991d3f-be69-4859-9c5d-ae5cd30bd229.pdf) |
| 2024-09-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f5760d9-e479-40ac-9b8a-2dec8ee3d46e.pdf) |
| 2024-05-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64265712-b2ba-413d-a9cd-5aa8cf9ba131.pdf) |
| 2023-10-19 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ad4701a-8de5-4e67-843d-36ae0967f1d5.pdf) |
| 2023-05-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=693847c8-656b-4570-8efe-98aab9a15d62.pdf) |
| 2022-10-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c33e64b-698f-4a46-a263-e4a3f881b772.pdf) |
| 2022-05-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44970c71-bea6-4677-825e-71bbbd3d9d54.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:37:18.694Z.